RSV disease in infants and young children: Can we see a brighter future?
Respiratory syncytial virus (RSV) is a highly contagious seasonal virus and the leading cause of Lower Respiratory Tract Infections (LRTI), including pneumonia and bronchiolitis in children. RSV-related LRTI cause approximately 3 million hospitalizations and 120,000 deaths annually among children &l...
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Taylor & Francis Group
2022-11-01
|
| Series: | Human Vaccines & Immunotherapeutics |
| Subjects: | |
| Online Access: | http://dx.doi.org/10.1080/21645515.2022.2079322 |
| _version_ | 1797673191972274176 |
|---|---|
| author | Eugenio Baraldi Giovanni Checcucci Lisi Claudio Costantino Jon H. Heinrichs Paolo Manzoni Matteo Riccò Michelle Roberts Natalya Vassilouthis |
| author_facet | Eugenio Baraldi Giovanni Checcucci Lisi Claudio Costantino Jon H. Heinrichs Paolo Manzoni Matteo Riccò Michelle Roberts Natalya Vassilouthis |
| author_sort | Eugenio Baraldi |
| collection | DOAJ |
| description | Respiratory syncytial virus (RSV) is a highly contagious seasonal virus and the leading cause of Lower Respiratory Tract Infections (LRTI), including pneumonia and bronchiolitis in children. RSV-related LRTI cause approximately 3 million hospitalizations and 120,000 deaths annually among children <5 years of age. The majority of the burden of RSV occurs in previously healthy infants. Only a monoclonal antibody (mAb) has been approved against RSV infections in a restricted group, leaving an urgent unmet need for a large number of children potentially benefiting from preventive measures. Approaches under development include maternal vaccines to protect newborns, extended half-life monoclonal antibodies to provide rapid long-lasting protection, and pediatric vaccines. RSV has been identified as a major global priority but a solution to tackle this unmet need for all children has yet to be implemented. New technologies represent the avenue for effectively addressing the leading-cause of hospitalization in children <1 years old. |
| first_indexed | 2024-03-11T21:40:33Z |
| format | Article |
| id | doaj.art-440499be93cc43219a6b8ae2c0b4aac4 |
| institution | Directory Open Access Journal |
| issn | 2164-5515 2164-554X |
| language | English |
| last_indexed | 2024-03-11T21:40:33Z |
| publishDate | 2022-11-01 |
| publisher | Taylor & Francis Group |
| record_format | Article |
| series | Human Vaccines & Immunotherapeutics |
| spelling | doaj.art-440499be93cc43219a6b8ae2c0b4aac42023-09-26T13:19:07ZengTaylor & Francis GroupHuman Vaccines & Immunotherapeutics2164-55152164-554X2022-11-0118410.1080/21645515.2022.20793222079322RSV disease in infants and young children: Can we see a brighter future?Eugenio Baraldi0Giovanni Checcucci Lisi1Claudio Costantino2Jon H. Heinrichs3Paolo Manzoni4Matteo Riccò5Michelle Roberts6Natalya Vassilouthis7University Hospital of PadovaSanofiUniversity of PalermoSanofiUniversity Hospital Degli InfermiServizio di Prevenzione e Sicurezza Negli Ambienti di Lavoro (SPSAL), AUSL—IRCCS di Reggio EmiliaSanofiSanofiRespiratory syncytial virus (RSV) is a highly contagious seasonal virus and the leading cause of Lower Respiratory Tract Infections (LRTI), including pneumonia and bronchiolitis in children. RSV-related LRTI cause approximately 3 million hospitalizations and 120,000 deaths annually among children <5 years of age. The majority of the burden of RSV occurs in previously healthy infants. Only a monoclonal antibody (mAb) has been approved against RSV infections in a restricted group, leaving an urgent unmet need for a large number of children potentially benefiting from preventive measures. Approaches under development include maternal vaccines to protect newborns, extended half-life monoclonal antibodies to provide rapid long-lasting protection, and pediatric vaccines. RSV has been identified as a major global priority but a solution to tackle this unmet need for all children has yet to be implemented. New technologies represent the avenue for effectively addressing the leading-cause of hospitalization in children <1 years old.http://dx.doi.org/10.1080/21645515.2022.2079322rsv all infantsrespiratory syncytial virusrsvrsv epidemiologyrsv paediatric burdenrsv preventionlrtirsv vaccinesmonoclonal antibodies |
| spellingShingle | Eugenio Baraldi Giovanni Checcucci Lisi Claudio Costantino Jon H. Heinrichs Paolo Manzoni Matteo Riccò Michelle Roberts Natalya Vassilouthis RSV disease in infants and young children: Can we see a brighter future? Human Vaccines & Immunotherapeutics rsv all infants respiratory syncytial virus rsv rsv epidemiology rsv paediatric burden rsv prevention lrti rsv vaccines monoclonal antibodies |
| title | RSV disease in infants and young children: Can we see a brighter future? |
| title_full | RSV disease in infants and young children: Can we see a brighter future? |
| title_fullStr | RSV disease in infants and young children: Can we see a brighter future? |
| title_full_unstemmed | RSV disease in infants and young children: Can we see a brighter future? |
| title_short | RSV disease in infants and young children: Can we see a brighter future? |
| title_sort | rsv disease in infants and young children can we see a brighter future |
| topic | rsv all infants respiratory syncytial virus rsv rsv epidemiology rsv paediatric burden rsv prevention lrti rsv vaccines monoclonal antibodies |
| url | http://dx.doi.org/10.1080/21645515.2022.2079322 |
| work_keys_str_mv | AT eugeniobaraldi rsvdiseaseininfantsandyoungchildrencanweseeabrighterfuture AT giovannicheccuccilisi rsvdiseaseininfantsandyoungchildrencanweseeabrighterfuture AT claudiocostantino rsvdiseaseininfantsandyoungchildrencanweseeabrighterfuture AT jonhheinrichs rsvdiseaseininfantsandyoungchildrencanweseeabrighterfuture AT paolomanzoni rsvdiseaseininfantsandyoungchildrencanweseeabrighterfuture AT matteoricco rsvdiseaseininfantsandyoungchildrencanweseeabrighterfuture AT michelleroberts rsvdiseaseininfantsandyoungchildrencanweseeabrighterfuture AT natalyavassilouthis rsvdiseaseininfantsandyoungchildrencanweseeabrighterfuture |